Clinical Chemotherapy ｜Laboratories｜Cancer Chemotherapy Center

Update : 2024/08/28

Overview

Our laboratory studies the resistant mechanisms and prediction of therapeutic effects of molecular target therapy by means of biochemistry, molecular biology, and cell imaging. We also carry out the collaborative investigation with the pathological laboratory and the treatment departments. Several national hospitals and public cancer centers have the laboratory which designated 'Laboratory of Clinical Chemotherapy' or 'Department of Clinical Chemotherapy' Among these laboratory, our division consists of physicians who hold the additional post in the 'clinical oncology' or 'hematology oncology' of the Cacner Institute Hospital as well as basic researchers, and promote collaborative investigation. As is known, in Japan, although the basic studies were superior, the application to a subsequent clinical development and a study to lead to new medicine concretely were not necessarily studied in enough excellent environment. Therefore we spend a power on the clinical data-managing, the processing, isolation, and preservation of specimens, and conduct the mediation with fundamental researches and the clinic in order to make good use of the kindness from patients.

Projects

The significance of circulating tumor cells and circulating endothelial cells in solid tumor
The clinical trial-based translational researches including breast cancer, bone-metastatic cancer and caner of unknown primary
Prediction of therapy effect of molecular target drugs and mutation analysis of the target molecules
sThe application of fluorescent imaging to the search of a biomarkers predicting the therapeutic effects
The application of fluorescent imaging to the diagnosis of hematopoietic tumors (fluorescence 3D blood atlas)
The functional analysis of novel protein RNF137 involved in antitumor effect of imatinib
The biomarker study in the gastrointestinal carcinoma chemotherapy
Discovery of novel biomarker and molecular target therapy, based on the carcinogenic mechanism in the urologic cancer

Publications

2024｜2023｜2022｜2021｜2020｜2019｜2018｜2017｜2016｜2015｜2014｜2013｜2012｜2011｜2010｜2009

2024

Ikarashi, D., *Kitano, S., Tsuyukubo, T., Yamashita, M., Matsuura, T., Maekawa, S., Kato, R., Kato, Y., Kanehira, M., Takata, R., Sugai, T., Obara, W.: Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer. Sci. Rep., 14 (1): 1442, 2024

2023

Chan, H. T., Nagayama, S., *Otaki, M., Chin, Y. M., Fukunaga, Y., Ueno, M., Nakamura, Y., Low, S. K.: Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Front. Oncol., 12: 1055968, 2023

2022

Kojima, T., Kato, K., Hara, H., *Takahashi, S., Muro, K., Nishina, T., Wakabayashi, M., Nomura, S., Sato, A., Ohtsu, A., *Doi, T.: Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). Esophagus, 19: 702-710. 2022
Shirouchi, Y., *Mishima, Y., Takayama, T., Minowa, S., Ishihara, Y., Tamba, M., Hirano, M., Onda, N., Takeuchi, K., Maruyama, D.: Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma. Biomed. Res., 43: 99-106. 2022
Takemoto, A., Takagi, S., Ukaji, T., Gyobu, N., Kakino, M., Takami, M., Kobayashi, A., Lebel, M., Kawaguchi, T., Sugawara, M., Tsuji-Takayama, K., Ichihara, K., Funauchi, Y., Ae, K., Matsumoto, S., Sugiura, Y., Takeuchi, K., Noda, T., Katayama, R., *Fujita, N.: Podoplanin antibody for osteosarcoma treatment. Clin. Cancer Res., 28: 2633-2645. 2022

2021

Takagi, S., Sasaki, Y., Koike, S., Takemoto, A., Seto, Y., Haraguchi, M., Ukaji, T., Kawaguchi, T., Sugawara, M., Saito, M., Funauchi, Y., Ae, K., Matsumoto, S., *Fujita, N., Katayama, R.: Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. Oncogene 40: 5548-5558. 2021
Ukaji, T., Takemoto, A., Shibata, H., Kakino, M., Takagi, S., Katayama, R., ^*Fujita, N.: Novel knock-in mouse model for the evaluation of therapeutic efficacy and toxicity of human podoplanin-targeting agents. Cancer Sci. 112: 2299-2313 (2021)
^*Mishima, Y., Mishima, Y., Shirouchi, Y., Nishimura, N., Yokoyama, M., Okabe, T., Inoue, N., Uryu, H., Fukuta, T., Hatake, K., Terui, Y.: The clonal evolution during long-term clinical course of multiple myeloma. Int. J. Hematol. 113: 279-284 (2021)

2020

Nosol, K., Romane, K., Irobalieva, R.N., Alam, A., Kowal, J., Fujita, N., ^*Locher, K.P.: Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1. Proc. Natl. Acad. Sci. USA 117: 26245-26253 (2020)

2019

Yokoyama M, Kusano Y, Nishihara A, Inoue N, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.: Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Support Care Cancer. 2019 May 15. doi: 10.1007/s00520-019-04802-4. (2019)

2018

Kusano Y, Yokoyama M, Inoue N, Yamauchi H, Takahashi A, Tsuyama N, Mishima Y, Nishimura N, Takeuchi K, Terui Y, Hatake K.: Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance.
Ann Hematol. 2018 Feb;97(2):289-297. (2018 )

2017

K. Hosoya, S. Matsusaka, T. Kashiwada, K. Suzuki, N. Ureshino, A. Sato, Y. Miki, K. Kitera, M. Hirai, K. Hatake, S. Kimura and N. Sueoka-Aragane.: Detection of KRAS mutations in plasma DNA using a fully automated Rrpid detection system in colorectal cancer patients.
Pathol. Oncol. Res., in press (2017)
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Ueda K, Kusano Y, Yamauchi H, Inoue N, Takahashi A, Tsuyama N, Mishima Y, Takeuchi K, Hatake K.: Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5+ DLBCL.
Br J Haematol. doi: 10.1111/bjh.15001. [Epub ahead of print] No abstract available. (2017)
Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda K, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.: Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer. 2017 Nov;25(11):3313-3320. (2017)
Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, Yokoyama M, Terui Y, Hatake K, Kitagawa M, Ishizuka N, Tomita N, Takeuchi K.: BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Blood. 130(4):489-500. (2017)
Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, Shibata H, Kuniyoshi R, Ogura M, Terui Y, Mizunuma N, Hatake K.: Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Target Oncol. 12(3):341-351. (2017)
Tsuyama N, Ennishi D, Yokoyama M, Baba S, Asaka R, Mishima Y, Terui Y, Hatake K, Takeuchi K.: Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Oncotarget. 8(20):33487-33500. (2017)
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Ueda K, Kusano Y, Yamauchi H, Inoue N, Takahashi A, Tsuyama N, Mishima Y, Takeuchi K, Hatake K.: Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5+ DLBCL.
Br J Haematol. doi: 10.1111/bjh.15001. (2017)
Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda K, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.: Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer. 2017 Nov;25(11):3313-3320. (2017)
Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, Yokoyama M, Terui Y, Hatake K, Kitagawa M, Ishizuka N, Tomita N, Takeuchi K.: BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Blood. 130(4):489-500. (2017)
Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, Shibata H, Kuniyoshi R, Ogura M, Terui Y, Mizunuma N, Hatake K.: Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Target Oncol. 12(3):341-351. (2017)
Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y, Hatake K, Sata N.: Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
Ann Nucl Med. 31(10):719-725. doi: 10.1007/s12149-017-1202-3. (2017)

2016

Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type. Dobashi A, Tsuyama N, Asaka R, Togashi Y, Ueda K, Sakata S, Baba S, Sakamoto K, Hatake K, Takeuchi K.: Genes Chromosomes Cancer. 2016 May;55(5):460-71. doi: 10.1002/gcc.22348. Epub 2016 Feb 10.
Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer. Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Horii R, Akiyama F, Iwase T, Ohno S, Hatake K, Hozumi Y, Sata N, Ito Y.: PLoS One. 2016 Sep 15;11(9):e0162616. doi: 10.1371/journal.pone.0162616.

2015

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Hatake K, Mizunuma N.: Mol Clin Oncol. 2015 Sep;3(5):1053-1057. Epub 2015 Jul 9.
Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Kobayashi K, Ito Y, Matsuura M, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, Hozumi Y, Yasuda Y, Hatake K.: Surg Today. 2015 Oct 14.
Suzuki SI, Matsusaka S, Hirai M, Shibata H, Takagi K, Mizunuma N, Hatake K.: A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol. 2015 Apr 30. doi: 10.3892/ijo.2015.2978. [Epub ahead of print]

2014

Matsusaka S, Kozuka M, Takagi H, Ito H, Minowa S, Hirai M, Hatake K.: A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid. Cancer Lett. 2014 Dec 1;355(1):113-20. doi: 10.1016/j.canlet.2014.09.009.
Kodama T, Motoi N, Ninomiya H, Sakamoto H, Kitada K, Tsukaguchi T, Satoh Y, Nomura K, Nagano H, Ishii N, Terui Y, Hatake K, Ishikawa Y.: A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line. J Thorac Oncol. 2014 Nov;9(11):1638-46. doi: 10.1097/JTO.0000000000000311.

2013

kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T, Hatake K.: Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 2013 Sep;33(9):3905-10.
Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, Fujita N.: Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One. 2013 Aug 21;8(8):e73609. doi: 10.1371/journal.pone.0073609.

2012

Mishima Y, Terui Y, Mishima Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, Hatake K.: High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism. Int Immunol. 2012 Mar 21. [Epub ahead of print]
Harada Y, Ishii I, Hatake K, Kasahara T.: Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett. 1;319(1):83-8. 2012

2011

Mishima Y, Terui Y, Takeuchi K, Matsumoto-Mishima Y, Matsusaka S, Utsubo-Kuniyoshi R and Hatake K.: The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer Journal (2011) 1, e15
Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K.: Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Cancer. 2011 Sep 1;117(17):4026-32.
Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I.: Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Sci. 2011 102(11):1949-57.
Takaba J, Mishima Y, Hatake K, Kasahara T.: Role of bone marrow-derived monocytes/macrophages in the repair of mucosal damage caused by irradiation and/or anticancer drugs in colitis model. Mediators Inflamm. 2010;2010:634145.

2010

Matsusaka, S., Chin, K., Ogura, M., Suenaga, M., Shinozaki, E., Mishima, Y., Terui, Y., Mizunuma, N., Hatake, K.: Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer.
Cancer Sci, 101, 1067-1071 (2010)

2009

Mishima, Y., Sugimura, N., Matsumoto-Mishima, Y., Terui, Y., Takeuchi, K., Asai, S., Ennishi, D., Asai, H., Yokoyama, M., Kojima, K., Hatake, K.: An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Clin Cancer Res, 15, 3624-3632 (2009)
Terui, Y., Mishima, Y., Sugimura, N., Kojima, K., Sakurai, T., Kuniyoshi, R., Taniyama, A., Yokoyama, M., Sakajiri, S., Takeuchi, K., Watanabe, C., Takahashi, S., Ito, Y., Hatake, K.: Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Clin Cancer Res, 15, 2523-2530 (2009)

Contact

Naoya Fujita（Acting Chief）
3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
Tel：81-3-3570-0508 Fax：81-3-3570-0465
E-mail：naoya.fujita@jfcr.or.jp